CYTOMX THERAPEUTICS, INC.
CTMX US23284F1057
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Belvin Marcia VP |
2.69 USD |
13,884 Sold |
37,334 USD |
13/06/2025 | 16/06/2025 |
| Ogden Christopher CFO |
2.69 USD |
10,614 Sold |
28,540 USD |
13/06/2025 | 16/06/2025 |
| Mccarthy Sean A. CEO |
2.69 USD |
55,511 Sold |
149,264 USD |
13/06/2025 | 16/06/2025 |
| Mccarthy Sean A. CEO |
2.69 USD |
55,511 Sold |
149,264 USD |
13/06/2025 | 16/06/2025 |
| Ogden Christopher CFO |
2.95 USD |
1,641 Sold |
4,841 USD |
13/06/2025 | 13/06/2025 |
| Rowland Lloyd A SR OFF |
0.60 USD |
10,203 Sold |
6,112 USD |
18/03/2025 | 18/03/2025 |
| Chu Yu-waye CMO |
0.60 USD |
4,025 Sold |
2,411 USD |
18/03/2025 | 18/03/2025 |
| Belvin Marcia VP |
0.60 USD |
19,512 Sold |
11,688 USD |
18/03/2025 | 18/03/2025 |
| Mccarthy Sean A. CEO |
0.60 USD |
37,656 Sold |
22,556 USD |
18/03/2025 | 18/03/2025 |
| Ogden Christopher CFO |
0.60 USD |
8,551 Sold |
5,122 USD |
18/03/2025 | 18/03/2025 |